Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB-3028 |
| Synonyms | |
| Therapy Description |
AB-3028 comprises autologous T-lymphocytes engineered to express a logic-gated chimeric antigen receptor (CAR) targeting tumor antigens and shRNA-miR modules targeting FAS and TGFBR2, which potentially inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 256). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB-3028 | AB3028|AB 3028 | AB-3028 comprises autologous T-lymphocytes engineered to express a logic-gated chimeric antigen receptor (CAR) targeting tumor antigens and shRNA-miR modules targeting FAS and TGFBR2, which potentially inhibits tumor growth (Journal for ImmunoTherapy of Cancer 2025;13, Suppl_2, 256). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07285694 | Phase Ib/II | AB-3028 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | Recruiting | USA | 0 |